There has been little hoopla or fanfare on these results which is odd. The lead researcher, Dr. Jay Schneider, is receiving plenty of local press. It looks like recruitment for Phase III is posted on his Thomas Jefferson U's

http://www.jefferson.edu/jmc/departm...unct-ther.html

Funny, they do not include the name of the substance under study? It is not listed at clinicaltrials.gov??

I was cautiously optimistic to read this quote from a local paper:

Over a 2-1/2 year period, not only did we see an improvement in their symptoms,” Schneider says, “but the progression of their symptoms was so slow that they weren’t even back to where they were at baseline.”

This falls in line with what Ceregene and Amgen were showing...that neurons are more impaired or clogged up as I think Girija has said. The researcher I spoke with from Ceregene basically said they were surprised by results as they implied neurons were functionally impaired or at least some were.

Laura